FOSL2 and breast carcinoma: (2) The increased acetylation at K703 disrupts the transcriptional potency of Sp1, reduces the binding of Sp1 to the FOSL2 promoter, causes the transcriptional suppression of FOSL2, alters the activity of downstream FOSL2 targets, and finally inhibits breast cancer cell growth and metastasis.